Terra Innovatum, GSR III Acquisition Corp. Approve $130 Million Merger

October 7, 2025 — Terra Innovatum Srl, a developer of micro-modular nuclear reactors, and GSR III Acquisition Corp. (NASDAQ:GSRT) announced that shareholders have approved their proposed business combination, paving the way for Terra Innovatum to become a publicly traded company.

The deal, valued at $130 million in total proceeds, received approval at GSR III’s Extraordinary General Meeting of Shareholders on October 7. The merger is expected to close in the coming days, subject to customary conditions. The combined company will operate under the name Terra Innovatum Global N.V., with its shares expected to trade on Nasdaq under the ticker “NKLR.”

Terra Innovatum CEO Alessandro Petruzzi said the approval represents a major step toward bringing the company’s low-cost, zero-carbon microreactor technology to market.

“We’re one step closer to becoming the first publicly traded nuclear reactor developer with a scalable design ready for commercialization by 2028,” Petruzzi said. “The proceeds will allow us to complete licensing, build and operate our first reactor, and position us for growth.”

The company’s microreactor, branded SOLO™, runs on widely available LEU fuel and uses off-the-shelf components, aimed at providing reliable, low-emission energy.

Giordano Morichi, Terra Innovatum’s Chief Business Development Officer, said the merger strengthens the firm’s financial foundation.

“This transaction enables us to bring SOLO™ to market and expand our operations with the support of a global investor base,” Morichi said.

Once finalized, the merger will make Terra Innovatum one of the few nuclear technology developers to go public via a SPAC transaction in recent years.

ABOUT TERRA INNOVATUM & SOLO™

Terra Innovatum’s mission is to make nuclear power accessible. We deliver simple and safe micro-reactor solutions that are scalable, affordable and deployable anywhere 1 MWe at a time.

Terra Innovatum is a pioneering force in the energy sector, dedicated to delivering innovative and sustainable power solutions. Terra Innovatum plans to leverage cutting-edge nuclear technology through the SOLO™ Micro-Modular Reactor (SMR™) to provide efficient, safe, and environmentally conscious energy. With a mission to address global energy shortages, Terra Innovatum combines extensive expertise in nuclear industry design, manufacturing, and installation licensing to offer disruptive energy solutions. Committed to propelling technological advancements, Terra Innovatum and SOLO™ are dedicated to fostering prosperity and sustainability for humankind.

It is anticipated that SOLO™ will be available globally within the next three years. Conceptualized in 2018 and engineered over six years by experts in nuclear safety, licensing, innovation, and R&D, SOLO™ addresses pressing global energy demands with a market-ready solution. Built from readily available commercial off-the-shelf components, the proven licensing path for SOLO™ enables rapid deployment and minimizes supply chain risks, ensuring final cost predictability. Designed to adapt with evolving fuel options, SOLO™ supports both LEU+ and HALEU, offering a platform ready to transition to future fuel supplies.

SOLO™ will offer a wide range of versatile applications, providing CO2-free, behind-the-meter, and off-grid power solutions for data centers, mini-grids serving remote towns and villages, and large-scale industrial operations in hard-to-abate sectors like cement production, oil and gas, steel manufacturing, and mining. It also has the ability to supply heat for industrial applications and other specialized processes, including water treatment, desalination and co-generation. Thanks to its modular design, SOLO™ can easily scale to deliver up to 1GW or more of CO2-free power with a minimal footprint, making it an ideal solution for rapidly replacing fossil fuel-based thermal plants. Beyond electricity and heat generation, SOLO™ can also contribute to critical applications in the medical sector by producing radioisotopes essential for oncology research and cancer treatment.

To learn more, visit: www.terrainnovatum.com.

Disclaimer – This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.


Posted

in

by

Tags: